ConferenceJun 15, 2026134 days ago
Two-year Phase 3 CAHtalyst Pediatric data show improved growth outcomes in CAH
Neurocrine Biosciences presented data on CRENESSITY (crinecerfont) for Classic congenital adrenal hyperplasia at a medical meeting on Jun 15, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
DetailsData presented at a medical meeting
- Company
- Neurocrine Biosciences, Inc. NBIX
- Drug
- CRENESSITY (crinecerfont)
- For
- Classic congenital adrenal hyperplasia
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- Jun 15, 2026
- Source note
- At ENDO 2026, Neurocrine presented two-year Phase 3 CAHtalyst Pediatric data showing that children and adolescents with classic congenital adrenal hyperplasia treated with CRENESSITY and with advanced bone age at baseline had slowed bone age progression and improved predicted adult height.
- Checked
- Checked by a person when it was added
Check the sourcesdon’t take our word for it
- Source: prnewswire.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- NBIX headlines on this site
Neurocrine Biosciences, Inc.
2 upcoming · 1 past catalysts
More from NBIX